Litcius/Paper detail

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Μacut, Yulia Pokramovich, Mark E. Molitch, Nina Leonova, Gérald Raverot, Elena Grineva, Yury Poteshkin, Yossi Gilgun‐Sherki, W.H. Ludlam, Gary Patou, Asi Haviv, Murray B. Gordon, Nienke R. Biermasz, Шломо Мелмед, Christian J. Strasburger

2021The Lancet Diabetes & Endocrinology54 citationsDOIOpen Access PDF

Topics & Concepts

AcromegalyMedicineOctreotideLanreotideClinical endpointInternal medicinePasireotideSomatostatinPegvisomantPlaceboClinical trialGastroenterologyHormoneGrowth hormoneAlternative medicinePathologyPituitary Gland Disorders and TreatmentsGrowth Hormone and Insulin-like Growth FactorsAdrenal Hormones and Disorders
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial | Litcius